XML 50 R40.htm IDEA: XBRL DOCUMENT v3.25.3
Collaborative Arrangements and Licensing Agreements - AstraZeneca (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Agreement
Jun. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Agreement
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
AstraZeneca [Member]            
Collaborative Arrangements and Licensing Agreements [Abstract]            
Number of collaboration agreements (in Agreement) | Agreement 2     2    
Cumulative payments received $ 960,000     $ 960,000    
Revenue 27,128   $ 19,461 101,705 $ 47,106  
Deferred revenue $ 0     $ 0   $ 0
WAINUA [Member]            
Collaborative Arrangements and Licensing Agreements [Abstract]            
Number of collaboration agreements (in Agreement) | Agreement 1     1    
Cardiovascular, Renal and Metabolic Diseases [Member]            
Collaborative Arrangements and Licensing Agreements [Abstract]            
Number of collaboration agreements (in Agreement) | Agreement 1     1    
Revenue   $ 30,000        
Next payment to be achieved $ 20,000     $ 20,000